A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

BIIB078

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (21)

9007

Research Site, Sankt Gallen

10032

Research Site, New York

21287

Research Site, Baltimore

30322

Research Site, Atlanta

32224

Research Site, Jacksonville

33136

Research Site, Miami

37920

Research Site, Knoxville

63110

Research Site, St Louis

90048

Research Site, Los Angeles

94303

Research Site, Palo Alto

92037-0886

Research Site, La Jolla

02114

Research Site, Boston

68506-2960

Research Site, Lincoln

T2N 1N4

Research Site, Calgary

M4N 3M5

Research Site, Toronto

H3A 2B4

Research Site, Montreal

DUBLIN 8

Research Site, Dublin

3508 GA

Research Site, Utrecht

SE5 9RS

Research Site, London

S10 2HQ

Research Site, Sheffield

NW1 2PG

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY